|
1
|
Edwards BK, Ward E, Kohler BA, et al:
Annual report to the nation on the status of cancer, 1975–2006,
featuring colorectal cancer trends and impact of interventions
(risk factors, screening, and treatment) to reduce future rates.
Cancer. 116:544–573. 2010.
|
|
2
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Soda M, Choi YL, Enomoto M, et al:
Identification of the transforming EML4-ALK fusion gene in
non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dahabreh IJ, Linardou H, Siannis F, et al:
Somatic EGFR mutation and gene copy gain as predictive biomarkers
for response to tyrosine kinase inhibitors in non-small cell lung
cancer. Clin Cancer Res. 16:291–303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pao W, Miller VA, Politi KA, et al:
Acquired resistance of lung adenocarcinomas to gefitinib or
erlotinib is associated with a second mutation in the EGFR kinase
domain. PLoS Med. 2:e732005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Horn L and Pao W: EML4-ALK: honing in on a
new target in non-small-cell lung cancer. J Clin Oncol.
27:4232–4235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Koivunen JP, Mermel C, Zejnullahu K, et
al: EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in
lung cancer. Clin Cancer Res. 14:4275–4283. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guazzi S, Price M, De Felice M, et al:
Thyroid nuclear factor 1 (TTF-1) contains a homeodomain and
displays a novel DNA binding specificity. EMBO J. 9:3631–3639.
1990.PubMed/NCBI
|
|
9
|
Weir BA, Woo MS, Getz G, et al:
Characterizing the cancer genome in lung adenocarcinoma. Nature.
450:893–898. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kwei KA, Kim YH, Girard L, et al: Genomic
profiling identifies TITF1 as a lineage-specific oncogene amplified
in lung cancer. Oncogene. 27:3635–3640. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Winslow MM, Dayton TL, Verhaak RG, et al:
Suppression of lung adenocarcinoma progression by Nkx2-1. Nature.
473:101–104. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Civitareale D, Castelli MP, Falasca P, et
al: Thyroid transcription factor 1 activates the promoter of the
thyrotropin receptor gene. Mol Endocrinol. 7:1589–1595.
1993.PubMed/NCBI
|
|
13
|
Shimura H, Shimura Y, Ohmori M, et al:
Single strand DNA-binding proteins and thyroid transcription
factor-1 conjointly regulate thyrotropin receptor gene expression.
Mol Endocrinol. 9:527–539. 1995.
|
|
14
|
Davies TF, Yin X and Latif R: The genetics
of the thyroid stimulating hormone receptor: history and relevance.
Thyroid. 20:727–736. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hébrant A, van Staveren WC, Maenhaut C, et
al: Genetic hyperthyroidism: hyperthyroidism due to activating TSHR
mutations. Eur J Endocrinol. 164:1–9. 2011.PubMed/NCBI
|
|
16
|
Xing M, Usadel H, Cohen Y, et al:
Methylation of the thyroid-stimulating hormone receptor gene in
epithelial thyroid tumors: a marker of malignancy and a cause of
gene silencing. Cancer Res. 63:2316–2321. 2003.PubMed/NCBI
|
|
17
|
Führer D, Tannapfel A, Sabri O, et al: Two
somatic TSH receptor mutations in a patient with toxic
metastasising follicular thyroid carcinoma and non-functional lung
metastases. Endocr Relat Cancer. 10:591–600. 2003.PubMed/NCBI
|
|
18
|
Choi H, Kratz J, Pham P, et al:
Development of a practical fast mutation screening assay for human
lung adenocarcinoma. Int J Oncol. 40:1900–1906. 2012.PubMed/NCBI
|
|
19
|
Narumi S, Muroya K, Abe Y, et al: TSHR
mutations as a cause of congenital hypothyroidism in Japan: a
population-based genetic epidemiology study. J Clin Endocrinol
Metab. 94:1317–1323. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stevenson CS and Birrell MA: Moving
towards a new generation of animal models for asthma and COPD with
improved clinical relevance. Pharmacol Ther. 130:93–105. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Whitsett J, Wert S and Weaver T: Alveolar
surfactant homeostasis and the pathogenesis of pulmonary disease.
Annu Rev Med. 61:105–119. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Spitz MR, Wei Q, Dong Q, et al: Genetic
susceptibility to lung cancer: the role of DNA damage and repair.
Cancer Epidemiol Biomarkers Prev. 12:689–698. 2003.PubMed/NCBI
|
|
23
|
Cohen BH: Chronic obstructive pulmonary
disease: a challenge in genetic epidemiology. Am J Epidemiol.
112:274–288. 1980.PubMed/NCBI
|
|
24
|
Sekine Y, Katsura H, Koh E, et al: Early
detection of COPD is important for lung cancer surveillance. Eur
Respir J. Nov 16–2011.(Epub ahead of print).
|
|
25
|
Skillrud DM, Offord KP and Miller RD:
Higher risk of lung cancer in chronic obstructive pulmonary
disease. A prospective matched, controlled study. Ann Intern Med.
105:503–507. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wright JG and Christman JW: The role of
nuclear factor kappaB in the pathogenesis of pulmonary diseases:
implications for therapy. Am J Respir Med. 2:211–219. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brody JS and Spira A: State of the art.
Chronic obstructive pulmonary disease, inflammation, and lung
cancer. Proc Am Thorac Soc. 3:535–537. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kraemer S, Rothe K, Pfaeffle R, et al:
Activating TSH-receptor mutation (Met453Thr) as a cause of
adenomatous non-autoimmune hyperthyroidism in a 3-year-old boy. J
Pediatr Endocrinol Metab. 22:269–274. 2009.PubMed/NCBI
|
|
29
|
Supornsilchai V, Sahakitrungruang T,
Wongjitrat N, et al: Expanding clinical spectrum of non-autoimmune
hyperthyroidism due to an activating germline mutation, p. M453T,
in the thyrotropin receptor gene. Clin Endocrinol. 70:623–628.
2009. View Article : Google Scholar : PubMed/NCBI
|
